These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35131876)

  • 1. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
    Bouleftour W; Guillot A; Magne N
    Mol Cancer Ther; 2022 Apr; 21(4):493-501. PubMed ID: 35131876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
    Bouleftour W; Sargos P; Magne N
    Curr Oncol Rep; 2023 Mar; 25(3):181-188. PubMed ID: 36696077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
    Wong JL; Rosenberg JE
    Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
    Hashimoto H; Tanaka Y; Murata M; Ito T
    Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence.
    Khosravanian MJ; Mirzaei Y; Mer AH; Keyhani-Khankahdani M; Abdinia FS; Misamogooe F; Amirkhani Z; Bagheri N; Meyfour A; Jahandideh S; Barpour N; Nikmanesh Y; Shahsavarani H; Abdollahpour-Alitappeh M
    Life Sci; 2024 Sep; 352():122910. PubMed ID: 39002610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Aggen DH; Chu CE; Rosenberg JE
    Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
    Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
    Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
    J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
    [No Abstract]   [Full Text] [Related]  

  • 12. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
    Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K
    Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
    Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
    Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
    Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
    Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.
    Weiten R; Bernhardt M; Niemann M; Kristiansen G; Grünwald V; Ritter M; Hölzel M; Eckstein M; Alajati A; Klümper N; Krausewitz P
    J Cell Mol Med; 2024 Jul; 28(14):e18572. PubMed ID: 39072867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 18. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
    Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
    Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
    Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.